← Back to Search

Checkpoint Inhibitor

DCC-3014 + Avelumab for Sarcomas

Memorial Sloan Kettering Cancer Center, New York, NY
Targeting 7 different conditionsDCC-3014 +1 morePhase 1Waitlist AvailableLed by Sandra D'Angelo, MDResearch Sponsored by Memorial Sloan Kettering Cancer Center

Study Summary

This trial is testing a new drug combo to see if it's safe for people with advanced sarcomas.

Eligible Conditions
  • Sarcoma
  • Liposarcoma
  • Leiomyosarcoma
  • Pleomorphic Sarcoma
  • Myxofibrosarcoma

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with advanced high-grade sarcoma that has spread to other parts of the body or is locally advanced.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated dose
Overall Response Rate

Side effects data

From 2020 Phase 2 trial • 19 Patients • NCT03006848
Musculoskeletal and connective tissue disorders
Injury, poisoning and procedural complications
Gastrointestinal disorders
General disorders and administration site conditions
Immune system disorders
Cardiac disorders
Nervous system disorders
Endocrine disorders
Metabolism and nutrition disorders
Blood and lymphatic system disorders
Neoplasms benign, malignant and unspecified
Respiratory, thoracic and mediastinal disorders
Infections and infestations
Renal and urinary disorders
Skin and subcutaneous tissue disorders
Study treatment Arm

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Advanced High-grade SarcomaExperimental Treatment2 Interventions
Dose Escalation: Up to 18 pts with locally advanced or metastatic high-grade sarcomas Dose Expansion: 10 pts per each diagnosis - undifferentiated pleomorphic sarcoma or myxofibrosarcoma, Leiomyosarcoma, Dedifferentiated liposarcoma
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,909 Previous Clinical Trials
588,862 Total Patients Enrolled
69 Trials studying Sarcoma
13,582 Patients Enrolled for Sarcoma
Sandra D'Angelo, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
185 Total Patients Enrolled
3 Trials studying Sarcoma
143 Patients Enrolled for Sarcoma

Media Library

Avelumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04242238 — Phase 1
Sarcoma Research Study Groups: Advanced High-grade Sarcoma
Sarcoma Clinical Trial 2023: Avelumab Highlights & Side Effects. Trial Name: NCT04242238 — Phase 1
Avelumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04242238 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total enrollment capacity for this medical research?

"At present, this trial is not looking for participants. The original posting was on January 22nd 2020 with the last update made in October 26th 2022. If you are curious about other studies focussing on sarcoma and DCC-3014 specifically, there are currently 478 and 111 trials recruiting patients respectively."

Answered by AI

Are new participants being accepted to this research project?

"Unfortunately, this medical trial is not presently enlisting participants. Initially posted on January 22nd 2020 and adjusted as of October 26th 2022 - if you seek other clinical trials, there are 478 studies actively recruiting sarcoma patients and 111 for DCC-3014 looking for volunteers."

Answered by AI

Has DCC-3014 been evaluated in past studies?

"Currently, 111 trials for DCC-3014 are currently in progress, with 10 of them being Phase 3. These studies have been established across 3678 centres; the majority being located in Barcelona and South Dakota."

Answered by AI

Has the FDA officially sanctioned DCC-3014?

"The team at Power gave DCC-3014 a score of 1 due to its Phase 1 status, indicating there is minimal evidence supporting safety and efficacy."

Answered by AI

Has a similar research effort ever been undertaken before?

"EMD Serono Research & Development Institute, Inc. kickstarted the exploration of DCC-3014 back in 2014 by running a 204 patient trial and subsequently gained approval for Phase 2 clinical trials. As it stands today, there are 111 live studies being conducted worldwide across 1024 cities spread over 52 countries."

Answered by AI
~1 spots leftby Jan 2024